evrazkarЕвразийский Кардиологический ЖурналEurasian heart journal2225-16852305-0748Евразийская ассоциация кардиологов10.38109/2225-1685-2023-1-86-92evrazkar-6368Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL PAPERSВлияние комбинированного применения аторвастатина и курцетина на биомаркеры воспаления у больных нестабильной стенокардией, после COVID-19 («Долгий COVID»)Effects of the combined use of atorvastatin and curcetin on inflammatory biomarkers in patients with unstable angina after COVID-19 (“Long COVID”)https://orcid.org/0000-0003-3936-0815АлиеваР. Б.AlievaR. B.

Алиева Рано Бурхановна, кандидат медицинских наук, старший научный сотрудник лаборатории ИБС

улица Осиё, дом 4, Мирзо-Улугбекский район, г. Ташкент 100052

Rano B. Alieva, Cand. of Sci. (Med.), Senior Researcher, IHD Laboratory

Osiyo street, house 4, Mirzo-Ulugbek district, Tashkent 100052

https://orcid.org/0000-0001-9195-7649ФозиловХ. Г.FozilovKh. G.

Фозилов Хуршид Гайратович, кандидат медицинских наук, директор

улица Осиё, дом 4, Мирзо-Улугбекский район, г. Ташкент 100052

Khurshid G. Fozilov, Cand. of Sci. (Med.), Director

Osiyo street, house 4, Mirzo-Ulugbek district, Tashkent 100052

https://orcid.org/0000-0003-2354-1785ШекА. Б.ShekA. B.

Шек Александр Борисович, доктор медицинских наук, профессор, руководитель лаборатории ИБС и атеросклероза

улица Осиё, дом 4, Мирзо-Улугбекский район, г. Ташкент 100052

Aleksandr B. Shek, Dr. of Sci. (Med.), Professor, Head of the Laboratory of IHD and Atherosclerosis

Osiyo street, house 4, Mirzo-Ulugbek district, Tashkent 100052

cardiocenter@mail.ruhttps://orcid.org/0000-0003-0510-336XХошимовШ. У.KhoshimovSh. U.

Хошимов Шавкат Уразалиевич, кандидат медицинских наук, старший научный сотрудник лаборатории ИБС

улица Осиё, дом 4, Мирзо-Улугбекский район, г. Ташкент 100052

Shavkat U. Khoshimov, Candidate of Medical Sciences, Senior Researcher, IHD Laboratory

Osiyo street, house 4, Mirzo-Ulugbek district, Tashkent 100052

https://orcid.org/0000-0002-6989-8950МусабаевМ. М.MusabaevM. M.

Мусабаев Мурат Мухтарович, заведующий клинико-биохимической лабораторией

улица Осиё, дом 4, Мирзо-Улугбекский район, г. Ташкент 100052

Murat M. Musabaev, Head of Clinical and Biochemical Laboratory

Osiyo street, house 4, Mirzo-Ulugbek district, Tashkent 100052

https://orcid.org/0000-0002-5606-6645КанЛ. Э.KanL. E.

Кан Лилия Эдуардовна, младший научный сотрудник лаборатории ИБС

улица Осиё, дом 4, Мирзо-Улугбекский район, г. Ташкент 100052

Liliya E. Kan, Junior Researcher, IHD Laboratory

Osiyo street, house 4, Mirzo-Ulugbek district, Tashkent 100052

https://orcid.org/0000-0002-4476-3910КимА. Р.KimA. R.

Ким Андрей Рудольфович, младший научный сотрудник лаборатории ИБС

улица Осиё, дом 4, Мирзо-Улугбекский район, г. Ташкент 100052

Andrey R. Kim, Junior Researcher, IHD Laboratory

Osiyo street, house 4, Mirzo-Ulugbek district, Tashkent 100052

ХодиметоваШ. А.KhodimetovaSh. A.

Ходиметова Шоира Ашировна, научный сотрудник лаборатории ИБС

улица Осиё, дом 4, Мирзо-Улугбекский район, г. Ташкент 100052

Shoira A. Khodimetova, Researcher, IHD Laboratory

Osiyo street, house 4, Mirzo-Ulugbek district, Tashkent 100052

Республиканский специализированный научно-практический медицинский центр кардиологии МЗ РУзУзбекистанRepublican Specialized Scientific and Practical Medical Center for CardiologyUzbekistan202301032023018692Copyright © Алиева Р.Б., Фозилов Х.Г., Шек А.Б., Хошимов Ш.У., Мусабаев М.М., Кан Л.Э., Ким А.Р., Ходиметова Ш.А., 20232023Алиева Р.Б., Фозилов Х.Г., Шек А.Б., Хошимов Ш.У., Мусабаев М.М., Кан Л.Э., Ким А.Р., Ходиметова Ш.А.Alieva R.B., Fozilov K.G., Shek A.B., Khoshimov S.U., Musabaev M.M., Kan L.E., Kim A.R., Khodimetova S.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.heartj.asia/jour/article/view/6368Цель

Цель: Сравнить влияние монотерапии аторвастатином и комбинированного применения аторвастатина с курцетином (смесь биофлавоноидов куркумина и кверцетина) на липидный спектр и биомаркеры воспаления у больных нестабильной стенокардией, после COVID-19 («Долгий COVID»).

Материал и методы

Материал и методы. Проведено открытое простое сравнительное рандомизированное исследование 186 больных с диагнозом: ИБС. Прогрессирующая стенокардия напряжения, в том числе 77 (I группа) пациентов, у которых дестабилизация стенокардии возникла вследствие перенесенного COVID-19 в течение 4-8 недель до включения в исследование, и 109 пациентов (II группа), у которых дестабилизация не имела связи с перенесенной инфекцией.

Результаты

Результаты: В I группе уровень вчС-реактивного белка [5,4 (2,06-7,4) г/л и IL-6 8,6 (5,4-10,3) пг/мл] был выше (Р < 0,05), чем во II группе больных [3,8 (1,2-4,0) г/л и 6,9 (2,2-10,2) пг/мл], соответственно. В I подгруппе больных, перенесших COVID-19, монотерапия аторвастатином (n = 43) не оказала значительного эффекта при двухмесячном лечении, тогда как во II подгруппе комбинированное применение аторвастатина с курцетином (n = 34) в течение 2 месяцев снизило уровень вчСРБ на 49,0% (Р < 0,05) и IL-6 на 40,0% (Р < 0,05).

Заключение

Заключение. У больных нестабильной стенокардией после COVID-19 комбинированное лечение аторвастатином с курцетином снижало концентрацию биомаркеров воспаления в отличие от монотерапии аторвастатином.

Objective

Objective: To compare the effects of atorvastatin monotherapy and the combination of atorvastatin with curcetin (a mixture of the bioflavonoids curcumin and quercetin) on lipid profile and inflammatory biomarkers in patients with unstable angina after COVID-19 (“Long COVID”).

Material

Material. An open simple comparative randomized study was conducted in 186 patients with unstable angina, including 77 (Group I) in whom angina destabilization occurred as a result of COVID-19 during 4-8 weeks prior to inclusion in the study, and 109 patients (Group II) in whom destabilization was not associated with infection.

Results

Results: In group I, the level of hsC-reactive protein [5,4 (2,06-7,4) g/l and IL-6 8,6 (5,4-10,3) pg/ml] was higher (P < 0,05) than in group II patients [3,8 (1,2-4,0) g/l and 6,9 (2,2-10,2) pg/ml], respectively. In subgroup I of patients after COVID-19, atorvastatin monotherapy (n = 43) did not have a significant effect after two months of treatment, while in subgroup II the combined use of atorvastatin with curcetin (n = 34) for 2 months reduced the level of hsCRP by 49,0% (P < 0,05) and Il-6 by 40,0% (P < 0,05).

Conclusion

Conclusion. In patients with unstable angina after COVID-19, combination treatment with atorvastatin and curcetin reduced concentrations of inflammatory biomarkers compared with atorvastatin monotherapy.

долгий COVIDнестабильная стенокардиякуркуминкверцетинlong COVIDinflammation biomarkerscurcuminquercetinИсследование выполнено по гранту Министерства инновационного развития Республики Узбекистан (№ государственной регистрации PZ-202007041)The study was supported by a research grant from the Ministry of Innovative Development of Uzbekistan (State Registration No. PZ-202007041)ReferencesPuntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020;5:1265–1273.Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020;5:1265–1273.Kotecha T, Knight DS, Razvi Y, Kumar K, Vimalesvaran K, Thornton G, et al. Patterns of myocardial injury in recovered troponinpositive COVID-19 patients assessed by cardiovascular magnetic resonance. European Heart Journal. (2021) 1866–1878. doi: 10.3410/f.739571449.793583038Kotecha T, Knight DS, Razvi Y, Kumar K, Vimalesvaran K, Thornton G, et al. Patterns of myocardial injury in recovered troponinpositive COVID-19 patients assessed by cardiovascular magnetic resonance. European Heart Journal. (2021) 1866–1878. doi: 10.3410/f.739571449.793583038Thornton GD, Shetye A, Knight DS, Knott K., et al. Myocardial Perfusion Imaging After Severe COVID-19 Infection Demonstrates Regional Ischemia Rather Than Global Blood Flow Reduction. Front Cardiovasc Med 2021 Dec 7;8:764599. doi: 10.3389/fcvm.2021.764599. eCollection 2021.Thornton GD, Shetye A, Knight DS, Knott K., et al. Myocardial Perfusion Imaging After Severe COVID-19 Infection Demonstrates Regional Ischemia Rather Than Global Blood Flow Reduction. Front Cardiovasc Med 2021 Dec 7;8:764599. doi: 10.3389/fcvm.2021.764599. eCollection 2021.Venkatesan, P. NICE guideline on long COVID – The Lancet Respiratory Medicine. Lancet Respir. Med. 2021;9(2):129. doi: 10.1016/s2213-2600(21)00031-xVenkatesan, P. NICE guideline on long COVID – The Lancet Respiratory Medicine. Lancet Respir. Med. 2021;9(2):129. doi: 10.1016/s2213-2600(21)00031-xNalbandian, A. et al. Post-acute COVID-19 syndrome. Nat. Med. 2021 Apr;27(4):601-615. doi: 10.1038/s41591-021-01283-zNalbandian, A. et al. Post-acute COVID-19 syndrome. Nat. Med. 2021 Apr;27(4):601-615. doi: 10.1038/s41591-021-01283-zDatta, S. D., Talwar, A. & Lee, J. T. A proposed framework and timeline of the spectrum of disease due to SARS-CoV-2 infection: Illness beyond acute infection and public health implications. JAMA 2020 Dec 8;324(22):2251-2252. doi: 10.1001/jama.2020.22717Datta, S. D., Talwar, A. & Lee, J. T. A proposed framework and timeline of the spectrum of disease due to SARS-CoV-2 infection: Illness beyond acute infection and public health implications. JAMA 2020 Dec 8;324(22):2251-2252. doi: 10.1001/jama.2020.22717Greenhalgh, T., Knight, M., Buxton, M. & Husain, L. Management of post-acute Covid-19 in primary care. BMJ 2020 Aug 11;370:m3026. doi: 10.1136/bmj.m3026Greenhalgh, T., Knight, M., Buxton, M. & Husain, L. Management of post-acute Covid-19 in primary care. BMJ 2020 Aug 11;370:m3026. doi: 10.1136/bmj.m3026An Y-W, Song S, Li W-X, Chen Y-X et al. Liver function recovery of COVID-19 patients after discharge, a follow-up study. Int J Med Sci 18: 176–186, 2021. doi: 10.7150/ijms.50691An Y-W, Song S, Li W-X, Chen Y-X et al. Liver function recovery of COVID-19 patients after discharge, a follow-up study. Int J Med Sci 18: 176–186, 2021. doi: 10.7150/ijms.50691Wang Y, Liu S, Liu H, Li W et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J Hepatol 73: 807-816, 2020. doi: 10.1016/j.jhep.2020.05.002Wang Y, Liu S, Liu H, Li W et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J Hepatol 73: 807-816, 2020. doi: 10.1016/j.jhep.2020.05.002Spearman CW, Aghemo A, Valenti L, Sonderup MW. COVID-19 and the liver: a 2021 update. Liver Int 41: 1988–1998, 2021. doi: 10.1111/liv.14984Spearman CW, Aghemo A, Valenti L, Sonderup MW. COVID-19 and the liver: a 2021 update. Liver Int 41: 1988–1998, 2021. doi: 10.1111/liv.14984Amar D. Desai,* Michael Lavelle,* Brian C. Boursiquot, and Elaine Y. Wan. Long-term complications of COVID-19. Am J Physiol Cell Physiol 2022 Jan 1;322(1):C1-C11. doi: 10.1152/ajpcell.00375.2021Amar D. Desai,* Michael Lavelle,* Brian C. Boursiquot, and Elaine Y. Wan. Long-term complications of COVID-19. Am J Physiol Cell Physiol 2022 Jan 1;322(1):C1-C11. doi: 10.1152/ajpcell.00375.2021Raman B, Bluemke DA, Lüscher TF, and Neubauer S. Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus European Heart Journal. 2022 Mar 14;43(11):1157-1172. doi: 10.1093/eurheartj/ehac031Raman B, Bluemke DA, Lüscher TF, and Neubauer S. Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus European Heart Journal. 2022 Mar 14;43(11):1157-1172. doi: 10.1093/eurheartj/ehac031Di Filippo L, De Lorenzo R, D’Amico M, Sofia V et al. COVID-19 is associated with clinically significant weight loss and risk of malnutrition, independent of hospitalisation: a post-hoc analysis of a prospective cohort study. Clin Nutr 2021 Apr;40(4):2420-2426. doi: 10.1016/j.clnu.2020.10.043Di Filippo L, De Lorenzo R, D’Amico M, Sofia V et al. COVID-19 is associated with clinically significant weight loss and risk of malnutrition, independent of hospitalisation: a post-hoc analysis of a prospective cohort study. Clin Nutr 2021 Apr;40(4):2420-2426. doi: 10.1016/j.clnu.2020.10.043Morley JE, Kalantar-Zadeh K, Anker SD. COVID-19: a major cause of cachexia and sarcopenia? J Cachexia Sarcopenia Muscle. 2020 Aug;11(4):863-865. doi: 10.1002/jcsm.12589Morley JE, Kalantar-Zadeh K, Anker SD. COVID-19: a major cause of cachexia and sarcopenia? J Cachexia Sarcopenia Muscle. 2020 Aug;11(4):863-865. doi: 10.1002/jcsm.12589Tersalvi G, Vicenzi M, Calabretta D, Biasco L, Pedrazzini G, Winterton D. Elevated troponin in patients with Coronavirus Disease 2019 (COVID-19): possible mechanisms. J Card Fail. 2020. doi: 10.1016/j.cardfail.2020.04.009Tersalvi G, Vicenzi M, Calabretta D, Biasco L, Pedrazzini G, Winterton D. Elevated troponin in patients with Coronavirus Disease 2019 (COVID-19): possible mechanisms. J Card Fail. 2020. doi: 10.1016/j.cardfail.2020.04.009National Institute for Health and Care Excellence. COVID-19 Rapid Guideline: Managing the Long-Term Effects of COVID-19. 2020. Available online: https://www.nice.org.uk/guidance/ng188/chapter/context#post-covid-19-syndrome (accessed on 28 January 2021).National Institute for Health and Care Excellence. COVID-19 Rapid Guideline: Managing the Long-Term Effects of COVID-19. 2020. Available online: https://www.nice.org.uk/guidance/ng188/chapter/context#post-covid-19-syndrome (accessed on 28 January 2021).Toraih, EA, Elshazli, RM, Hussein, MH, Elgaml, A, Amin, M, El-Mowafy, M, et al.. Association of cardiac biomarkers and comorbidities with increased mortality, severity, and cardiac injury in COVID-19 patients: a meta-regression and decision tree analysis. J Med Virol 2020 Nov;92(11):2473-2488. doi: 10.1002/jmv.26166Toraih, EA, Elshazli, RM, Hussein, MH, Elgaml, A, Amin, M, El-Mowafy, M, et al.. Association of cardiac biomarkers and comorbidities with increased mortality, severity, and cardiac injury in COVID-19 patients: a meta-regression and decision tree analysis. J Med Virol 2020 Nov;92(11):2473-2488. doi: 10.1002/jmv.26166Guzik TJ, Mohiddin SA, Dimarco A, Patel V, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res 116: 1666–1687, 2020. doi:10.1093/cvr/cvaa106Guzik TJ, Mohiddin SA, Dimarco A, Patel V, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res 116: 1666–1687, 2020. doi:10.1093/cvr/cvaa106Chou CH, Hung CS, Liao CW, Wei LH, Chen CW, Shun CT, Wen WF, Wan CH, Wu XM, Chang YY, Wu VC, Wu KD, Lin YH, TAIPAI Study Group. IL-6 transsignalling contributes to aldosterone-induced cardiac fibrosis. Cardiovasc Res 2018; 114:690–702.Chou CH, Hung CS, Liao CW, Wei LH, Chen CW, Shun CT, Wen WF, Wan CH, Wu XM, Chang YY, Wu VC, Wu KD, Lin YH, TAIPAI Study Group. IL-6 transsignalling contributes to aldosterone-induced cardiac fibrosis. Cardiovasc Res 2018; 114:690–702.Watson C, Whittaker S, Smith N, Vora AJ, Dumonde DC, Brown KA. IL-6 acts on endothelial cells to preferentially increase their adherence for lymphocytes. Clin Exp Immunol 1996;105:112–119.Watson C, Whittaker S, Smith N, Vora AJ, Dumonde DC, Brown KA. IL-6 acts on endothelial cells to preferentially increase their adherence for lymphocytes. Clin Exp Immunol 1996;105:112–119.van Tits LJ, Stienstra R, van Lent PL, Netea MG, Joosten LA, Stalenhoef AF. Oxidized LDL enhances pro-inflammatory responses of alternatively activated M2 macrophages: a crucial role for Kruppel-like factor 2. Atherosclerosis 2011;214:345–349.van Tits LJ, Stienstra R, van Lent PL, Netea MG, Joosten LA, Stalenhoef AF. Oxidized LDL enhances pro-inflammatory responses of alternatively activated M2 macrophages: a crucial role for Kruppel-like factor 2. Atherosclerosis 2011;214:345–349.Deftereos SG, Giannopoulos G, Vrachatis DA, et al Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019The GRECCO-19 Randomized Clinical Trial. JAMA Netw Open. 2020;3(6):e2013136. doi: 10.1001/jamanetworkopen.2020.13136Deftereos SG, Giannopoulos G, Vrachatis DA, et al Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019The GRECCO-19 Randomized Clinical Trial. JAMA Netw Open. 2020;3(6):e2013136. doi: 10.1001/jamanetworkopen.2020.13136Pourdowlat G, Saghafi F, Mozafari A, Sahebnasagh A et al Efficacy and safety of colchicine treatment in patients with COVID-19: A prospective, multicenter, randomized clinical trial. Phytotherapy Research. 2022 Feb;36(2):891-898. doi: 10.1002/ptr.7319Pourdowlat G, Saghafi F, Mozafari A, Sahebnasagh A et al Efficacy and safety of colchicine treatment in patients with COVID-19: A prospective, multicenter, randomized clinical trial. Phytotherapy Research. 2022 Feb;36(2):891-898. doi: 10.1002/ptr.7319COVID-19 Scientific Advisory Group Rapid Evidence Report Colchicine for the treatment of COVID-19, February 23, 2021COVID-19 Scientific Advisory Group Rapid Evidence Report Colchicine for the treatment of COVID-19, February 23, 2021Zhen-Zhen Wang ZZ, Li K, Maskey AR, Huang W, Toutov AA. A small molecule compound berberine as an orally active therapeutic candidate against COVID-19 and SARS: A computational and mechanistic study. The FASEB Journal. 2021;35:e21360.Zhen-Zhen Wang ZZ, Li K, Maskey AR, Huang W, Toutov AA. A small molecule compound berberine as an orally active therapeutic candidate against COVID-19 and SARS: A computational and mechanistic study. The FASEB Journal. 2021;35:e21360.Zhang BY, Chen M, Chen XC, Cao K, You Y et al. Berberine reduces circulating inflammatory mediators in patients with severe COVID-19 BJS, 2021, 108, e9–e11Zhang BY, Chen M, Chen XC, Cao K, You Y et al. Berberine reduces circulating inflammatory mediators in patients with severe COVID-19 BJS, 2021, 108, e9–e11Bernini R and Velotti F. Natural Polyphenols as Immunomodulators to Rescue Immune Response Homeostasis: Quercetin as a Research Model against Severe COVID-19. Molecules 2021 Sep 25;26(19):5803. doi: 10.3390/molecules26195803Bernini R and Velotti F. Natural Polyphenols as Immunomodulators to Rescue Immune Response Homeostasis: Quercetin as a Research Model against Severe COVID-19. Molecules 2021 Sep 25;26(19):5803. doi: 10.3390/molecules26195803Saeedi-Boroujeni A and Mahmoudian-Sani MR. Anti-inflammatory potential of Quercetin in COVID-19 treatment. Journal of Inflammation. 2021 Jan 28;18(1):3. doi: 10.1186/s12950-021-00268-6Saeedi-Boroujeni A and Mahmoudian-Sani MR. Anti-inflammatory potential of Quercetin in COVID-19 treatment. Journal of Inflammation. 2021 Jan 28;18(1):3. doi: 10.1186/s12950-021-00268-6Rattis BA, Ramos SG and Celes MR. Curcumin as a potencial treatment for COVID-19. Frontiers in pharmacology, 2021 May, v. 12, article 675287Rattis BA, Ramos SG and Celes MR. Curcumin as a potencial treatment for COVID-19. Frontiers in pharmacology, 2021 May, v. 12, article 675287Vahedian-Azimi A, Abbasifard M, Rahimi-Bashar F, Guest PC et al. Effectiveness of Curcumin on Outcomes of Hospitalized COVID-19 Patients: A Systematic Review of Clinical Trials. Nutrients. 2022 Jan 7;14(2):256. doi: 10.3390/nu14020256Vahedian-Azimi A, Abbasifard M, Rahimi-Bashar F, Guest PC et al. Effectiveness of Curcumin on Outcomes of Hospitalized COVID-19 Patients: A Systematic Review of Clinical Trials. Nutrients. 2022 Jan 7;14(2):256. doi: 10.3390/nu14020256Ruscica M., Penson P.E., Ferri N., Zhisheng J., Zirlik A. Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases – A position paper from the International Lipid Expert Panel (ILEP). Progress in Cardiovascular diseases. 2021 Jul-Aug;67:40-52. doi: 10.1016/j.pcad.2021.06.010Ruscica M., Penson P.E., Ferri N., Zhisheng J., Zirlik A. Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases – A position paper from the International Lipid Expert Panel (ILEP). Progress in Cardiovascular diseases. 2021 Jul-Aug;67:40-52. doi: 10.1016/j.pcad.2021.06.010Heeba GH, Mahmoud ME, El Hanafy AA. Anti-inflammatory potential of curcumin and quercetin in rats: role of oxidative stress, heme oxygenase-1 and TNF-α. Toxicol Ind Health. 2014 Jul;30(6):551-60. doi: 10.1177/0748233712462444. Epub 2012 Sep 28.Heeba GH, Mahmoud ME, El Hanafy AA. Anti-inflammatory potential of curcumin and quercetin in rats: role of oxidative stress, heme oxygenase-1 and TNF-α. Toxicol Ind Health. 2014 Jul;30(6):551-60. doi: 10.1177/0748233712462444. Epub 2012 Sep 28.Güran M, Şanlıtürk G, Kerküklü NR, Altundağ EM, Süha Yalçın A. Combined effects of quercetin and curcumin on anti-inflammatory and antimicrobial parameters in vitro. Eur J Pharmacol. 2019 Sep 15;859:172486. doi: 10.1016/j.ejphar.2019.172486. Epub 2019 Jun 25.Güran M, Şanlıtürk G, Kerküklü NR, Altundağ EM, Süha Yalçın A. Combined effects of quercetin and curcumin on anti-inflammatory and antimicrobial parameters in vitro. Eur J Pharmacol. 2019 Sep 15;859:172486. doi: 10.1016/j.ejphar.2019.172486. Epub 2019 Jun 25.

The authors declare that there are no conflicts of interest present.